Arcosa Discloses Merger Litigation and Supplemental Proxy Disclosures Ahead of Sept 4 Vote
ACA sits 63% above its 52-week low of $89.03.
Summary
Arcosa disclosed two stockholder lawsuits and fifteen demand letters challenging its merger proxy disclosures, and voluntarily supplemented the proxy with detailed financial advisor analyses to moot the claims ahead of the September 4, 2026 shareholder vote.
Key Events · M&A and Partnerships · ACA
-
Merger Litigation Filed
Two purported stockholder actions (Floyd v. Arcosa and Hamilton v. Arcosa) were filed in New York Supreme Court on August 12-13, 2026, alleging the proxy statement omitted material information and asserting negligent misrepresentation, concealment, and negligence claims.
-
Fifteen Demand Letters Received
Arcosa received fifteen demand letters from purported stockholders, two with draft complaints alleging violations of Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9, requesting corrective disclosures.
-
Supplemental Proxy Disclosures
To moot the claims and avoid delay, Arcosa voluntarily supplemented the proxy with Evercore's DCF analysis (implied equity value $88.10-$143.20/share), selected public company trading analysis ($122.40-$155.50/share), and Goldman Sachs' illustrative present values ($112.03-$142.31/share), all compared to the $150.00 merger consideration.
-
No New Management Arrangements
The supplemental disclosure confirms no directors or executive officers have entered into new employment, compensation, or other agreements with the Company or Parent in connection with the merger, and the merger is not conditioned on any such arrangements.
Analysis · ACA · Manufacturing
Two stockholder lawsuits and fifteen demand letters allege the proxy statement omitted material information needed to vote on the $150/share CRH acquisition. Arcosa denies the claims but voluntarily supplemented the proxy with detailed financial advisor analyses — Evercore's DCF and trading multiples, and Goldman Sachs' illustrative present values — to moot the litigation and avoid delay. The supplemental disclosures show implied equity values ranging from $88.10 to $155.50 per share, with the $150 merger consideration near the top of most ranges, reinforcing the board's view that the price is fair. The special meeting is set for September 4, 2026, and this filing is aimed at keeping that timeline on track.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACA was trading at $145.27 on NYSE in the Manufacturing sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $89.03 to $146.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.